Sugi Predict

Sugi Predict / Compounds / SCHEMBL1638828

SCHEMBL1638828

SCHEMBL1638828

CC(=O)c1ccc2nc(N)sc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ LMNA P02545 3/20 0.59
▸ ALDH1A1 P00352 3/20 0.59
▸ LCK P06239 1/20 0.59
▸ MAPT P10636 2/20 0.57
▸ GAA P10253 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ CYP2D6 P10635 2/20 0.56
▸ CYP3A4 P08684 2/20 0.54
▸ CYP2C9 P11712 2/20 0.54
▸ HPGD P15428 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP2C19 P33261 2/20 0.53
▸ AXL P30530 1/20 0.53
▸ GFER P55789 1/20 0.53
▸ SCN4A P35499 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4655242 0.94 RAB9A (0.55) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL9185252 0.87 RAB9A (0.53) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL31132400 0.87 RAB9A (0.53) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL3113684 0.85 RAB9A (0.61) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL211024 0.85 RAB9A (0.66) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL30563626 0.85 RAB9A (0.61) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL799211 0.84 PIK3CA (0.64) —
Hydrochloric Acid SCHEMBL4680538 0.83 RAB9A (0.64) RAB9ANPC1LMNAALDH1A1LCK
Bromide SCHEMBL10947640 0.83 RAB9A (0.64) RAB9ANPC1LMNAALDH1A1LCK
SCHEMBL27549467 0.83 RAB9A (0.59) RAB9ANPC1LMNAALDH1A1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098292-A1 New Compounds Useful for Treating CNS Disorders ASTRAZENECA AB (SE) 2011-04-28 — — US claimed
EP-1765815-A2 NEW COMPOUNDS USEFUL FOR TREATING CNS DISORDERS AstraZeneca AB (SE) 2007-03-28 — — EP claimed
WO-2006004507-A2 NEW BENZOTHIAZOLE DERIVATIVES USEFUL FOR TREATING CNS DISORDERS ASTRAZENECA AB (SE) 2006-01-12 — — WO claimed
CN-118666864-A Pyrimidine-thiophene-benzothiazole compound or pharmaceutically acceptable salt thereof, and preparation and application thereof 皖南医学院 2024-09-20 — — CN disclosed
EP-3487498-B1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF ZHANG XIAOHU (CN) 2023-09-06 — — EP disclosed
EP-3487498-B1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF ZHANG XIAOHU (CN) 2023-09-06 — — EP disclosed
US-20230210966-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF LION BIOTECHNOLOGIES, INC. 2023-07-06 — — US disclosed
US-11357841-B2 Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof IOVANCE BIOTHERAPEUTICS, INC. (US) 2022-06-14 — — US disclosed
US-10815226-B2 Heteroaryl compounds as inhibitors of necrosis, composition and application thereof ACCRO BIOSCIENCE INC. (KY) 2020-10-27 — — US disclosed
US-10815226-B2 Heteroaryl compounds as inhibitors of necrosis, composition and application thereof ACCRO BIOSCIENCE INC. (KY) 2020-10-27 — — US disclosed
EP-3225618-B1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2020-05-06 — — EP disclosed
WO-2001057008-A1 2-BENZOTHIAZOLYL UREA DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS ABBOTT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG & COMPANY KOMMANDITGESELLSCHAFT (DE) 2001-08-09 — — WO disclosed
US-4552952-A Disperse and acid azo dyes having one or two cinnamoyl substituents on a benzothiazole or benzoisothiazole diazonium moiety and having an aniline, tetrahydroquinoline or benzomorpholine type coupler EASTMAN KODAK COMPANY (US) 1985-11-12 — — US disclosed
US-4118384-A DIAZOTIZATION BAYER AKTIENGESELLSCHAFT (DE) 1978-10-03 — — US disclosed
US-4085099-A AZO DYES PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1978-04-18 — — US disclosed
US-4060544-A COUPLERS GAF CORPORATION (US) 1977-11-29 — — US disclosed
US-4039524-A Keto-amido containing phenylazo benzothiazole dyestuffs GAF CORPORATION (US) 1977-08-02 — — US disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 — — US disclosed
US-3933423-A Azoic dyeing of leather E. I. DU PONT DE NEMOURS AND COMPANY (US) 1976-01-20 — — US disclosed
US-3931145-A POLYESTER GAF CORPORATION (US) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210966-A1 EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF KCNN3, KCNK3, KCNA3 RAB9A 3724/4885NPC1 1119/4885LMNA 3777/4885
US-11357841-B2 Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof KCNN3, KCNK3, KCNA3 RAB9A 3724/4885NPC1 1119/4885LMNA 3777/4885
US-10815226-B2 Heteroaryl compounds as inhibitors of necrosis, composition and application thereof LITAF, BAX, TNF RAB9A 1997/4885NPC1 200/4885LMNA 279/4885
US-20110098292-A1 New Compounds Useful for Treating CNS Disorders SLC18A2, PMP22, GAP43 RAB9A 726/4885NPC1 84/4885LMNA 2675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.